BSX
Boston Scientific Corp
$44.81
-0.49 (-1.08%)
At close · Jul 8
Market Cap
$66.87B
Shares
1,486,355,179
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$20.07B
+19.9%
FY2025
Net Income
$2.89B
+56.7%
FY2025
Gross Margin
69.01%
+0.4pp
FY2025
Operating Margin
18%
+2.5pp
FY2025
Diluted EPS
$1.94
+55.2%
FY2025
Operating Cash Flow
$4.53B
+32%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $20.61B | $20.07B | $16.75B | $14.24B | $12.68B | $11.89B | $9.91B | $10.74B | $9.82B | $9.05B | $9.08B | $8.07B | $7.46B | $7.14B | $7.25B | $7.62B | $7.81B | $8.19B | |
| $6.36B | $6.22B | $5.26B | $4.35B | $3.96B | $3.71B | $3.47B | $3.12B | $2.81B | $2.59B | $2.42B | $2.17B | $2.21B | $2.17B | $2.35B | $2.66B | $2.6B | $2.58B | |
| $14.26B | $13.85B | $11.49B | $9.9B | $8.73B | $8.18B | $6.45B | $7.62B | $7.01B | $6.46B | $5.96B | $5.3B | $5.17B | $4.97B | $4.9B | $4.96B | $5.21B | $5.61B | |
| — | 69.01% | 68.61% | 69.49% | 68.81% | 68.78% | 65.05% | 70.98% | 71.37% | 71.34% | 65.69% | 65.74% | 69.28% | 69.56% | 67.6% | 65.11% | 66.71% | 68.54% | |
| $2.13B | $2.05B | $1.62B | $1.41B | $1.32B | $1.2B | $1.14B | $1.17B | $1.11B | $997M | $920M | $876M | $817M | $861M | $886M | $895M | $939M | $1.04B | |
| $7.07B | $6.89B | $5.98B | $5.19B | $4.52B | $4.36B | $3.79B | $3.94B | $3.57B | $3.29B | $3.1B | $2.87B | $2.9B | $2.67B | $2.54B | $2.49B | $2.58B | $2.64B | |
| $910M | $897M | $856M | $828M | $803M | $741M | $789M | $699M | $599M | $565M | $545M | $495M | $438M | $410M | $395M | $421M | $513M | $511M | |
| — | $1.37B | $1.27B | $1.2B | $1.14B | $1.09B | $1.12B | $1.01B | $894M | $844M | $815M | $769M | $725M | $689M | $683M | $717M | $816M | $834M | |
| $94M | $101M | $16M | $69M | $24M | $40M | $52M | $38M | $36M | $37M | $28M | $26M | $69M | $456M | $355M | $220M | $116M | $63M | |
| $10.47B | $10.24B | $8.89B | $7.55B | $7.08B | $6.98B | $6.53B | $6.1B | $5.5B | $5.17B | $5.52B | $5.63B | $5.47B | $4.85B | $8.77B | $4.06B | $5.86B | $6.51B | |
| $3.79B | $3.61B | $2.6B | $2.34B | $1.65B | $1.2B | -$80M | $1.52B | $1.51B | $1.29B | $447M | -$327M | -$301M | $120M | -$3.87B | $904M | -$656M | -$894M | |
| — | 18% | 15.54% | 16.45% | 13% | 10.09% | -0.81% | 14.14% | 15.33% | 14.2% | 4.93% | -4.05% | -4.03% | 1.68% | -53.36% | 11.86% | -8.4% | -10.92% | |
| — | $4.98B | $3.87B | $3.54B | $2.79B | $2.29B | $1.04B | $2.53B | $2.4B | $2.13B | $1.26B | $442M | $424M | $809M | -$3.19B | $1.62B | $160M | -$60M | |
| $357M | $349M | $305M | $265M | $470M | $341M | $361M | $473M | $241M | $229M | $233M | $284M | $216M | $324M | $261M | $281M | $393M | $407M | |
| -$51M | -$228M | -$321M | -$358M | -$508M | -$123M | $1M | -$831M | -$85M | -$353M | -$270M | -$323M | $8M | -$19M | -$239M | -$262M | -$407M | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $6M | — | |
| — | $139M | -$79M | -$59M | -$1M | $250M | $398M | -$30M | $155M | -$92M | -$21M | -$9M | $27M | -$9M | $37M | $27M | $4M | — | |
| $3.74B | $3.39B | $2.28B | $1.99B | $1.14B | $1.08B | -$79M | $687M | $1.42B | $933M | $177M | -$650M | -$509M | -$223M | -$4.11B | $642M | -$1.06B | -$1.31B | |
| $184M | $493M | $436M | $393M | $443M | $36M | $2M | -$4.01B | -$249M | $828M | -$170M | -$411M | -$390M | -$102M | -$39M | $201M | $2M | -$283M | |
| $3.56B | $2.89B | $1.85B | $1.59B | $698M | $1.04B | -$82M | $4.7B | $1.67B | $104M | $347M | -$239M | -$119M | -$121M | -$4.07B | $441M | -$1.07B | -$1.03B | |
| — | 14.41% | 11.02% | 11.18% | 5.5% | 8.76% | -0.83% | 43.78% | 17.01% | 1.15% | 3.82% | -2.96% | -1.59% | -1.69% | -56.12% | 5.79% | -13.64% | -12.52% | |
| -$6M | -$6M | -$8M | $1M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| $3.57B | $2.9B | $1.85B | $1.57B | $642M | $985M | -$115M | — | — | — | — | — | — | — | — | — | — | — | |
| $3.19B | $2.01B | $2.08B | $1.37B | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| USD/shares | — | $1.96 | $1.26 | $1.08 | $0.45 | $0.69 | -$0.08 | $3.38 | $1.21 | $0.08 | $0.26 | -$0.18 | -$0.09 | -$0.09 | -$2.89 | $0.29 | -$0.70 | -$0.68 |
| USD/shares | — | $1.94 | $1.25 | $1.07 | $0.45 | $0.69 | -$0.08 | $3.33 | $1.19 | $0.08 | $0.25 | -$0.18 | -$0.09 | -$0.09 | -$2.89 | $0.29 | -$0.70 | -$0.68 |
| shares | — | 1.48B | 1.47B | 1.45B | 1.43B | 1.42B | 1.42B | 1.39B | 1.38B | 1.37B | 1.36B | 1.34B | 1.32B | 1.34B | 1.41B | 1.51B | 1.52B | 1.51B |
| shares | — | 1.49B | 1.49B | 1.46B | 1.44B | 1.43B | 1.42B | 1.41B | 1.4B | 1.39B | 1.38B | 1.34B | 1.32B | 1.34B | 1.41B | 1.52B | 1.52B | 1.51B |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2011–FY2024: $2.25B in buybacks, $166M in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
3.71×
Medical Devices median 3.66×
EV/EBIT
20.15×
Medical Devices median 21.30×
P/E (TTM)
18.82×
Medical Devices median 26.84×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Cardiovascular | $13,250,000,000 | $10,755,000,000 | $8,819,000,000 | $7,831,000,000 | $7,242,000,000 | $5,866,000,000 | $4,208,000,000 | $3,777,000,000 |
| Medsurg | $6,824,000,000 | $5,993,000,000 | $5,422,000,000 | $4,911,000,000 | $4,633,000,000 | $3,827,000,000 | $3,307,000,000 | $3,007,000,000 |
| BSX Reportable Segments | — | — | — | — | — | $9,694,000,000 | $10,654,000,000 | — |
| Rhythm and Neuro | — | — | — | — | — | $2,752,000,000 | $3,140,000,000 | $3,041,000,000 |
| All Other Segments | — | — | — | — | — | — | $81,000,000 | — |
By Geography (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|
| United States | $12,864,000,000 | $10,210,000,000 | $8,425,000,000 | $7,632,000,000 | $6,911,000,000 | $5,701,000,000 | $6,167,000,000 | $5,538,000,000 |
| Non Us | $7,210,000,000 | $6,538,000,000 | $5,816,000,000 | $5,111,000,000 | $4,978,000,000 | $4,212,000,000 | $4,569,000,000 | $4,286,000,000 |
| EMEA | $3,451,000,000 | $3,228,000,000 | $2,856,000,000 | $2,526,000,000 | $2,518,000,000 | $2,097,000,000 | $2,264,000,000 | $2,176,000,000 |
| Asia Pacific | $3,080,000,000 | $2,686,000,000 | $2,400,000,000 | $2,116,000,000 | $2,070,000,000 | $1,781,000,000 | $1,898,000,000 | $1,727,000,000 |
| Emerging Markets | $2,985,000,000 | $2,680,000,000 | $2,310,000,000 | $1,968,000,000 | $1,656,000,000 | $1,138,000,000 | $1,282,000,000 | $1,097,000,000 |
| Latin America and Canada | $678,000,000 | $624,000,000 | $560,000,000 | $469,000,000 | $386,000,000 | $307,000,000 | $395,000,000 | $383,000,000 |
| US Excluding Other Net Sales | — | $10,210,000,000 | $8,425,000,000 | $7,632,000,000 | $6,901,000,000 | $5,508,000,000 | — | — |
By Product & Service (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Interventional Cardiology Vascular Therapies | $4,639,000,000 | $4,199,000,000 | $3,791,000,000 | — | — | — | — | — |
| Electrophysiology EP | $3,325,000,000 | $1,904,000,000 | $800,000,000 | $585,000,000 | $365,000,000 | $287,000,000 | — | — |
| Global Endoscopy Endo Reporting Unit | $2,916,000,000 | $2,687,000,000 | $2,482,000,000 | $2,221,000,000 | $2,141,000,000 | $1,780,000,000 | $1,894,000,000 | $1,762,000,000 |
| Global Urology and Pelvic Health Reporting Unit | $2,709,000,000 | $2,200,000,000 | $1,964,000,000 | $1,773,000,000 | $1,583,000,000 | $1,286,000,000 | $1,413,000,000 | $1,245,000,000 |
| Cardiac Rhythm Management | $2,332,000,000 | $2,279,000,000 | $2,218,000,000 | $2,100,000,000 | $2,019,000,000 | $1,704,000,000 | — | — |
| Watchman | $1,958,000,000 | $1,516,000,000 | $1,274,000,000 | $1,019,000,000 | $829,000,000 | $324,000,000 | — | — |
| Global Neuromodulation NM Reporting Unit | $1,199,000,000 | $1,106,000,000 | $976,000,000 | $917,000,000 | $909,000,000 | $761,000,000 | $873,000,000 | $779,000,000 |
| Interventional Oncology Embolization | $996,000,000 | $856,000,000 | $736,000,000 | — | — | — | — | — |
| Global Cardiology Reporting Unit | — | — | — | $5,932,000,000 | $5,422,000,000 | $4,290,000,000 | — | — |
| Global CRM Reporting Unit | — | — | — | — | $2,019,000,000 | $1,704,000,000 | $1,939,000,000 | $1,951,000,000 |
| Global Electrophysiology EP Reporting Unit | — | — | — | — | $365,000,000 | $287,000,000 | $329,000,000 | $311,000,000 |
| Global Interventional Cardiology IC Reporting Unit | — | — | — | — | $3,038,000,000 | $2,299,000,000 | $2,816,000,000 | $2,590,000,000 |
| Global Peripheral Interventions Pi Reporting Unit | — | — | — | $1,899,000,000 | $1,820,000,000 | $1,577,000,000 | $1,392,000,000 | $1,187,000,000 |
| Interventional Cardiology Therapies | — | — | — | $2,228,000,000 | $2,209,000,000 | $1,975,000,000 | — | — |
| Other | — | — | — | -$60,000,000 | $13,000,000 | $219,000,000 | — | — |
| Specialty Pharmaceuticals | — | — | — | — | $13,000,000 | $219,000,000 | $81,000,000 | — |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|
| Total Allocated To Reportable Segments | $3,737,000,000 | $3,412,000,000 | $2,198,000,000 | $3,007,000,000 | $2,875,000,000 | $2,509,000,000 |
| Other | -$60,000,000 | $4,000,000 | $143,000,000 | — | — | — |
| Cardiovascular | — | — | — | $1,137,000,000 | $1,117,000,000 | $988,000,000 |
| Medsurg | — | — | — | $1,204,000,000 | $1,102,000,000 | $984,000,000 |
| Rhythm and Neuro | — | — | — | $666,000,000 | $655,000,000 | $537,000,000 |
| Specialty Pharmaceuticals | — | $4,000,000 | $143,000,000 | $56,000,000 | — | — |
Operating Margin by Segment (%)
| Component | 2019-12-31 | 2018-12-31 |
|---|---|---|
| Cardiovascular | 27% | 29.6% |
| Medsurg | 36.4% | 36.6% |
| Rhythm and Neuro | 21.2% | 21.5% |
Key facts
CIK
885725
CUSIP
101137107
13F (30d)
102 filings
55 filers
Visit website
Investor relations